• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The role of dupilumab in the treatment of eosinophilic esophagitis.度普利尤单抗在嗜酸性粒细胞性食管炎治疗中的作用。
Immunotherapy. 2024;16(13):845-852. doi: 10.1080/1750743X.2024.2377060. Epub 2024 Jul 29.
2
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.度普利尤单抗治疗 1 至 11 岁患者的嗜酸性食管炎。
N Engl J Med. 2024 Jun 27;390(24):2239-2251. doi: 10.1056/NEJMoa2312282.
3
Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study.度普利尤单抗治疗嗜酸性食管炎儿童：一项回顾性多中心研究。
BMC Pediatr. 2025 Feb 5;25(1):100. doi: 10.1186/s12887-024-05313-w.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
Real-world Effectiveness of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis.度普利尤单抗治疗嗜酸性食管炎的真实世界疗效：一项系统评价和Meta分析
J Clin Gastroenterol. 2025 Jul 1;59(6):483-490. doi: 10.1097/MCG.0000000000002146.
6
Unravelling the pathogenesis of Eosinophilic Esophagitis from genetic predisposition to environmental triggers.揭示嗜酸性粒细胞性食管炎从遗传易感性到环境触发因素的发病机制。
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf039.
7
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.无论之前是否服用过布地奈德或氟替卡松，或之前是否与口服局部皮质类固醇一起使用过其他治疗方法，度普利尤单抗对嗜酸性食管炎均有效：3期随机、安慰剂对照、LIBERTY EoE TREET试验的结果。
Expert Rev Gastroenterol Hepatol. 2025 Jan-Feb;19(2):197-209. doi: 10.1080/17474124.2025.2461516. Epub 2025 Feb 5.
8
Systemic treatments for eczema: a network meta-analysis.湿疹的全身治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2.
9
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
10
Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis.度普利尤单抗治疗嗜酸性食管炎的不良反应：美国食品药品监督管理局不良事件报告系统数据库分析
Dis Esophagus. 2025 Jul 3;38(4). doi: 10.1093/dote/doaf055.

引用本文的文献

1
Efficacy of Dupilumab in the Treatment of Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.度普利尤单抗治疗嗜酸性食管炎的疗效：一项随机对照试验的系统评价和网状Meta分析
Life (Basel). 2025 Feb 17;15(2):307. doi: 10.3390/life15020307.

本文引用的文献

1
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.度普利尤单抗治疗 1 至 11 岁患者的嗜酸性食管炎。
N Engl J Med. 2024 Jun 27;390(24):2239-2251. doi: 10.1056/NEJMoa2312282.
2
Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.度普利尤单抗在青少年和成年嗜酸细胞性食管炎患者中无论既往是否使用过口服皮质类固醇均显示出疗效且具有良好的耐受性：3 期 LIBERTY EoE TREET 研究的亚组分析。
Gut. 2024 Feb 23;73(3):398-406. doi: 10.1136/gutjnl-2023-330220.
3
Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis.真实世界中度利尤单抗治疗重度、难治性、纤维化狭窄性嗜酸性粒细胞性食管炎患者的疗效。
Clin Gastroenterol Hepatol. 2024 Feb;22(2):252-258. doi: 10.1016/j.cgh.2023.08.015. Epub 2023 Sep 3.
4
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.度普利尤单抗治疗嗜酸性食管炎成人和青少年长达52周的疗效和安全性（LIBERTY EoE TREET研究）：一项多中心、双盲、随机、安慰剂对照的3期试验
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):990-1004. doi: 10.1016/S2468-1253(23)00204-2. Epub 2023 Aug 31.
5
Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center.在一家三级儿科医疗中心，儿童和青年嗜酸性粒细胞性食管炎患者使用度普利尤单抗的真实世界经验。
JPGN Rep. 2022 Feb 25;3(2):e180. doi: 10.1097/PG9.0000000000000180. eCollection 2022 May.
6
Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.度普利尤单抗与结膜炎之间的关联：一项对随机对照试验的系统评价和荟萃分析
Pharmaceutics. 2023 Mar 23;15(4):1031. doi: 10.3390/pharmaceutics15041031.
7
No association between dupilumab use and short-term cancer development in atopic dermatitis patients.度普利尤单抗的使用与特应性皮炎患者短期癌症发生之间无关联。
J Allergy Clin Immunol Pract. 2023 May;11(5):1548-1551. doi: 10.1016/j.jaip.2022.12.018. Epub 2022 Dec 26.
8
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.度普利尤单抗在成人和青少年嗜酸性食管炎中的应用。
N Engl J Med. 2022 Dec 22;387(25):2317-2330. doi: 10.1056/NEJMoa2205982.
9
Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick.度普利尤单抗用于嗜酸性食管炎的临床指南：一把衡量标准。
Ann Allergy Asthma Immunol. 2023 Mar;130(3):371-378. doi: 10.1016/j.anai.2022.12.014. Epub 2022 Dec 13.
10
Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab.使用度普利尤单抗治疗难治性小儿纤维狭窄性嗜酸性食管炎
ACG Case Rep J. 2022 Nov 11;9(11):e00887. doi: 10.14309/crj.0000000000000887. eCollection 2022 Nov.

度普利尤单抗在嗜酸性粒细胞性食管炎治疗中的作用。

The role of dupilumab in the treatment of eosinophilic esophagitis.

机构信息

Division of Gastroenterology & Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States.

Division of Allergy & Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, United States.

出版信息

Immunotherapy. 2024;16(13):845-852. doi: 10.1080/1750743X.2024.2377060. Epub 2024 Jul 29.

DOI:10.1080/1750743X.2024.2377060
PMID:39073081
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457672/
Abstract

Dupilumab has been approved to treat a variety of atopic disorders and was the first US FDA-approved medication for the treatment of eosinophilic esophagitis (EoE), initially approved in May 2022, with expansion in use to patients as young as 1 year of age weighing at least 15 kg in January 2024. It is a fully human monoclonal antibody that inhibits both IL-4 and IL-13 signaling, suppressing TH2-mediated proinflammatory cytokines, chemokines and IgE implicated in EoE pathogenesis. Phase II and III trials in EoE have demonstrated histologic, endoscopic and symptomatic improvement in disease activity with an overall favorable safety profile. This article will review the available clinical trial data and real-world efficacy of dupilumab in EoE.

摘要

度普利尤单抗已获准用于治疗多种特应性疾病，是美国食品药品监督管理局（FDA）批准的首款用于治疗嗜酸性食管炎（EoE）的药物，于 2022 年 5 月首次获批，2024 年 1 月适应证扩大至 1 岁及以上、体重大于或等于 15 kg 的患者。该药是一种全人源单克隆抗体，可同时抑制 IL-4 和 IL-13 信号通路，抑制 TH2 介导的促炎细胞因子、趋化因子和 IgE，这些因子与 EoE 的发病机制有关。EoE 的 II 期和 III 期临床试验显示，该药可改善组织学、内镜和症状，从而改善疾病活动度，且总体安全性良好。本文将综述度普利尤单抗在 EoE 中的现有临床试验数据和真实世界疗效。